卓正醫療 02677Prospectus Information

Prospectus Information
返回 Stock Info Prospectus Allotment Results Allotment Profile Expected Lots
IPO Timeline
Broker Deadline
2026-02-03
Morning deadline
HKEX Deadline
2026-02-03
Noon deadline
Broker Results (T-2)
2026-02-04
Some brokers release in afternoon
Grey Market (T-1)
2026-02-05
Afternoon
HKEX Allotment (T-1)
2026-02-05
Evening
Registrar Allotment (T-1)
2026-02-05
Evening
Listing Day (T)
2026-02-06
First day of trading
Company Overview
Stock Name卓正醫療
Stock Code02677
Company Full Name卓正醫療
IndustryBiotech & Pharma
Principal Activitiesprofession that demands lifelong learning
Listing Date2026-02-06
Listing Rules EraNew Rules (after Aug 2025)
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)Principal Place of Business in Hong Kong Room 1901, 19/F, Lee Garden One 33 Hysan Avenue Causeway Bay Hong Kong
Business Address (Hong Kong)香港 銅鑼灣 希慎道33號 利園一期19樓1901室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.distinctclinic.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contactand Transfer Campbells Corporate Services Limited
A-Share/US Dual ListingNo
Offering Information
Offering Mechanism Mechanism B
Offer PriceHK$ 59.90 / shares
Offer Price RangeFinal offer price only, no range
Lot Size50 shares
Entry ThresholdHK$ 2,995
Par ValueRMB 0.001 / shares
Offer Period2026-01-29 to 2026-02-03
Global Offering Shares4,750,000 shares
HK Public Offer Shares (Initial)475,000 shares (10.0%)
Public Offer Lots (Initial)9,500lots (4,750lots, 4,750lots)
International Placing Shares (Initial)4,275,000 shares (90.0%)
Offer Ratio~7.38%
Total Shares Post-IPO64,384,350 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share30.4%
Clawback Tiers机制B-无回补
Reallocation OptionNo
Total Global Offering SizeHK$ 284,525,000
Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 50 HK$ 2,995
2 lots 100 HK$ 5,990
3 lots 150 HK$ 8,985
4 lots 200 HK$ 11,980
5 lots 250 HK$ 14,975
6 lots 300 HK$ 17,970
7 lots 350 HK$ 20,965
8 lots 400 HK$ 23,960
9 lots 450 HK$ 26,955
10 lots 500 HK$ 29,950
12 lots 600 HK$ 35,940
14 lots 700 HK$ 41,930
16 lots 800 HK$ 47,920
18 lots 900 HK$ 53,910
20 lots 1,000 HK$ 59,900
30 lots 1,500 HK$ 89,850
40 lots 2,000 HK$ 119,800
50 lots 2,500 HK$ 149,750
60 lots 3,000 HK$ 179,700
70 lots 3,500 HK$ 209,650
80 lots 4,000 HK$ 239,600
90 lots 4,500 HK$ 269,550
100 lots 5,000 HK$ 299,500
120 lots 6,000 HK$ 359,400
140 lots 7,000 HK$ 419,300
160 lots 8,000 HK$ 479,200
180 lots 9,000 HK$ 539,100
200 lots 10,000 HK$ 599,000
400 lots 20,000 HK$ 1,198,000
600 lots 30,000 HK$ 1,797,000
800 lots 40,000 HK$ 2,396,000
1,000 lots 50,000 HK$ 2,995,000
1,200 lots 60,000 HK$ 3,594,000
1,400 lots 70,000 HK$ 4,193,000
1,600 lots 80,000 HK$ 4,792,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1,800 lots 90,000 HK$ 5,391,000
2,000 lots 100,000 HK$ 5,990,000
3,000 lots 150,000 HK$ 8,985,000
4,750 lots 237,500 HK$ 14,226,250
Valuation & Financials
Market Cap (at Offer Price)HK$ 3,856,622,565
Pre-IPO Valuation (Last Round)To be extracted
P/E Ratio不適用（公司處於虧損狀態）
Profit/Loss StatusNet loss RMB123.0 million
Period-End Cash Balance人民币226,100,000元
Listing ExpensesTo be extracted
Listing Expenses / Funds Raised~25.8%
Total Pre-IPO InvestmentTo be extracted
First Day Performance
First Day CloseHK$ 67.9
First Day OpenHK$ 81.0
First Day Change13.36%
First Day Volume2417400.0
First Day Turnover202700000.0
Use of Proceeds
Use of Proceeds1、35%或約76.7百萬港元用于通過打造一個醫療人工智能應用的專業人才 庫、與領先的科研機構及公司開展戰略合作及外部采購； 2、30%或約65.7百萬港元用于升級現有醫療服務機構及設立新醫療服務機 構，以加深滲透力及覆蓋更廣泛的目標患者群； 3、25%或約54.8百萬港元用于在適當機會出現時收購一線城市及新一線城市 中業績良好的醫療服務機構； 4、10%或約21.9百萬港元用作營運資金及其他一般公司用途。
Underwriting Syndicate
Joint Sponsors (2)
海通国际资本有限公司 CE ADQ859 浦银国际融资有限公司 CE BFZ375
Sponsor cum Overall Coordinator (2)
海通国际证券有限公司 CE AAF806 浦银国际融资有限公司 CE BFZ375
Overall Coordinators (5)
海通国际证券有限公司 CE AAF806 浦银国际融资有限公司 CE BFZ375 招银国际融资有限公司 CE AVM940 中国银河国际证券（香港）有限公司 CE AXM459 建银国际金融有限公司 CE AJO225
Joint Global Coordinators (9)
海通国际证券有限公司 CE AAF806 浦银国际融资有限公司 CE BFZ375 招银国际融资有限公司 CE AVM940 中国银河国际证券（香港）有限公司 CE AXM459 建银国际金融有限公司 CE AJO225 工银国际证券有限公司 CE ARO299 华兴证券（香港）有限公司 CE AZX839 中泰国际证券有限公司 CE BAA855 富途证券国际（香港）有限公司 CE AZT137
Joint Bookrunners (12)
海通国际证券有限公司 CE AAF806 浦银国际融资有限公司 CE BFZ375 招银国际融资有限公司 CE AVM940 中国银河国际证券（香港）有限公司 CE AXM459 建银国际金融有限公司 CE AJO225 工银国际证券有限公司 CE ARO299 华兴证券（香港）有限公司 CE AZX839 中泰国际证券有限公司 CE BAA855 富途证券国际（香港）有限公司 CE AZT137 睿本国际有限公司 CE BOP567 富德证券有限公司 CE BHT984 老虎证券（香港）环球有限公司 CE BMU940
Joint Lead Managers (12)
海通国际证券有限公司 CE AAF806 浦银国际融资有限公司 CE BFZ375 招银国际融资有限公司 CE AVM940 中国银河国际证券（香港）有限公司 CE AXM459 建银国际金融有限公司 CE AJO225 工银国际证券有限公司 CE ARO299 华兴证券（香港）有限公司 CE AZX839 中泰国际证券有限公司 CE BAA855 富途证券国际（香港）有限公司 CE AZT137 睿本国际有限公司 CE BOP567 富德证券有限公司 CE BHT984 老虎证券（香港）环球有限公司 CE BMU940
Capital Market Intermediaries (12)
海通国际证券有限公司 CE AAF806 浦银国际融资有限公司 CE BFZ375 招银国际融资有限公司 CE AVM940 中国银河国际证券（香港）有限公司 CE AXM459 建银国际金融有限公司 CE AJO225 工银国际证券有限公司 CE ARO299 华兴证券（香港）有限公司 CE AZX839 中泰国际证券有限公司 CE BAA855 富途证券国际（香港）有限公司 CE AZT137 睿本国际有限公司 CE BOP567 富德证券有限公司 CE BHT984 老虎证券（香港）环球有限公司 CE BMU940
Service Providers
RoleInstitution
Legal Advisor to Company 美迈斯律师事务所
竞天公诚律师事务所
凯博律师事务所
Helmsman LLC
Robin Lynn & Lee
Legal Advisor to Sponsors/Underwriters 苏利文•克伦威尔律师事务所（香港）有限法律责任合伙
通商律师事务所
Auditor and Reporting Accountant 罗兵咸永道会计师事务所
Industry Advisor 弗若斯特沙利文（北京）咨询有限公司上海分公司
Receiving Banks 招商永隆银行有限公司
Cornerstone Investors
#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 (%) (%) (%) (%)Health Vision 44,000,000 HKD 700,850 14.75% 1.09% 6 months 2026-08-06
2 金域医学检验 3,000,000 USD 372,650 7.85% 0.58% 6 months 2026-08-06
3 明略科技 2,000,000 USD 248,400 5.23% 0.39% 6 months 2026-08-06
4 Galaxy Dynasty 1,000,000 USD 124,200 2.61% 0.19% 6 months 2026-08-06
Directors & Management
Chairman王志遠
Company Secretary劉亦軒
執行董事 (2)
#NameEnglish NameType
1 王志远 — 執行董事
2 施翼 — 執行董事
非執行董事 (5)
#NameEnglish NameType
1 曹少山 — 非執行董事
2 张向东 — 非執行董事
3 魏国兴 — 非執行董事
4 陈小红 — 非執行董事
5 郝瑞 — 非執行董事
獨立非執行董事 (4)
#NameEnglish NameType
1 陈锐 — 獨立非執行董事
2 王咏刚 — 獨立非執行董事
3 王高飞 — 獨立非執行董事
4 高平阳 — 獨立非執行董事
Major Shareholders
Major Shareholders & HoldingsSUBSTANTIAL SHAREHOLDERS So far as our Directors are aware, immediately following the completion of the Global Offering (assuming the Over-allotment Option is not exercised), the following persons will have an interest or short position in the Shares or the underlying Share
AI AI Analysis
!
The following content is generated by an AI model based on historical IPO data. It does NOT constitute investment advice, solicitation, or recommendation. Past subscription patterns and post-listing performance do not guarantee future results. Data may contain inaccuracies — always verify against official HKEX filings and prospectuses before making any investment decision.

Market Sentiment

The IPO was massively oversubscribed by 2,730 times, signaling extreme market enthusiasm and scarce allocation. With a near-zero hit rate, most applicants received no shares, reflecting intense demand for this healthcare listing. The final offer price was set at HK$59.9, within the expected range, but the overwhelming subscription left many investors empty-handed. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

The A-tail (80,000 lots) expected 0.6403 lots, nearly identical to the 0.6437 lots for B-head (90,000 lots), making the larger B-head subscription highly inefficient. Investors in B-head locked up significantly more capital but gained merely 0.0034 extra lots, eroding returns after broker fees. This anomaly highlights minimal incremental benefit from crossing into the B-tier for this IPO. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

Mainland Chinese applicants comprised 55.8% of successful holders, suggesting strong cross-border interest and potential familiarity with the healthcare sector. The male-dominated profile (65.6%) and average age of 42.8 years point to a risk-tolerant, middle-aged investor base. Although regional data is not available, such mainland concentration often implies Guangdong province dominance. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

AI-generated content. For informational purposes only. Not financial advice. Verify against official sources.
Offering Structure
Subscription Tiers
IPO Timeline
Disclaimer & Risk Warning

Site Nature: This website (cibo.qizai.ai) is an independent technology product showcase platform established by Panda Securities Limited (CE Number: BNC380). This website itself and all content displayed herein do not constitute and are not involved in any regulated activity or licensed service.

Not Investment Advice: The data on this page is automatically extracted from prospectus PDFs by AI and may contain omissions or errors. All information and data on this page are sourced from prospectuses and related historical documents, are not real-time data, and will not be automatically updated, reflecting historical information at the time of prospectus publication. All content is provided solely for AI tool analysis learning exchange and technical reference purposes, and absolutely does not constitute any investment advice, offer to buy or sell, solicitation, recommendation, or guarantee. The output of this AI analysis tool should not be interpreted as investment opinion.

Decision Responsibility: Users should make investment decisions based on their own independent judgment and consult independent licensed financial advisors when needed. Neither the Company nor this AI analysis tool shall bear any responsibility for any investment decisions made by users based on the information on this page.

Separation from Panda Securities Official Website: The content of this website is strictly distinct from the SFC-regulated licensed services provided by Panda Securities' official website (fafa.hk). No securities trading or account opening or other regulated operations can be conducted through this website.

Panda Securities Limited is a licensed corporation regulated by the Hong Kong SFC (CE Number: BNC380) and a Hong Kong Exchange Participant (Participant ID: 02229). Use of this website constitutes acceptance of this disclaimer.

Cibo — IPO & Market Data Analytics